Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7
Avadel Pharmaceuticals (Nasdaq: AVDL) has scheduled its second quarter 2025 financial results conference call and webcast for August 7, 2025, at 8:30 a.m. ET. The presentation will include a corporate update and discussion of financial results for the quarter ended June 30, 2025.
Investors can access the live audio webcast through the company's website at www.avadel.com, with a replay available for 90 days following the event. Participants are encouraged to register for the conference call at least 10 minutes before the start time.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha programmato la conference call e il webcast per la presentazione dei risultati finanziari del secondo trimestre 2025 per il 7 agosto 2025 alle 8:30 ET. La presentazione includerà un aggiornamento aziendale e una discussione sui risultati finanziari del trimestre conclusosi il 30 giugno 2025.
Gli investitori potranno seguire la trasmissione audio in diretta tramite il sito web della società all'indirizzo www.avadel.com, con la possibilità di riascoltare la registrazione per 90 giorni dopo l'evento. Si consiglia ai partecipanti di registrarsi alla conference call almeno 10 minuti prima dell'orario di inizio.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha programado su llamada y webcast para presentar los resultados financieros del segundo trimestre de 2025 para el 7 de agosto de 2025 a las 8:30 a.m. ET. La presentación incluirá una actualización corporativa y una discusión sobre los resultados financieros del trimestre terminado el 30 de junio de 2025.
Los inversores podrán acceder a la transmisión de audio en vivo a través del sitio web de la compañía en www.avadel.com, con una repetición disponible durante 90 días después del evento. Se recomienda a los participantes registrarse para la llamada al menos 10 minutos antes del inicio.
Avadel Pharmaceuticals (나스닥: AVDL)은 2025년 2분기 재무 결과 컨퍼런스 콜 및 웹캐스트를 2025년 8월 7일 오전 8시 30분(동부시간)에 예정했습니다. 발표에는 기업 현황 업데이트와 2025년 6월 30일 종료된 분기의 재무 결과에 대한 논의가 포함됩니다.
투자자들은 회사 웹사이트 www.avadel.com을 통해 라이브 오디오 웹캐스트에 접속할 수 있으며, 이벤트 종료 후 90일 동안 재청취가 가능합니다. 참가자들은 시작 시간 최소 10분 전에 컨퍼런스 콜에 등록할 것을 권장합니다.
Avadel Pharmaceuticals (Nasdaq : AVDL) a programmé sa conférence téléphonique et webcast pour les résultats financiers du deuxième trimestre 2025 le 7 août 2025 à 8h30 ET. La présentation comprendra une mise à jour de l'entreprise ainsi qu'une discussion des résultats financiers pour le trimestre clos le 30 juin 2025.
Les investisseurs pourront accéder au webcast audio en direct via le site web de la société à l'adresse www.avadel.com, avec une rediffusion disponible pendant 90 jours après l'événement. Il est recommandé aux participants de s'inscrire à la conférence téléphonique au moins 10 minutes avant le début.
Avadel Pharmaceuticals (Nasdaq: AVDL) hat seine Telefonkonferenz und Webcast zur Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 7. August 2025 um 8:30 Uhr ET geplant. Die Präsentation umfasst ein Unternehmensupdate und die Besprechung der Finanzergebnisse für das Quartal, das am 30. Juni 2025 endete.
Investoren können den Live-Audio-Webcast über die Website des Unternehmens unter www.avadel.com verfolgen; eine Aufzeichnung ist 90 Tage nach der Veranstaltung verfügbar. Teilnehmer werden gebeten, sich mindestens 10 Minuten vor Beginn der Telefonkonferenz zu registrieren.
- None.
- None.
DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 7, 2025, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2025.
A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696
Media Contact:
Alyssa Ramirez
Real Chemistry
aramirez@realchemistry.com
FAQ
When is Avadel Pharmaceuticals (AVDL) reporting Q2 2025 earnings?
How can investors access Avadel's Q2 2025 earnings call?
What period will Avadel's Q2 2025 financial results cover?
How early should participants register for Avadel's Q2 earnings call?
